#ASCO16 and #skincancer #cancerawareness

Skin cancer: pembrolizumab gives '40% melanoma survival' #ImmunoOnc #ASCO16 https://t.co/Z1B6F4wfB8

— Miguel Perales M.D. (@DrMiguelPerales) May 19, 2016